Avita Medical financials
$11.96+2.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Jun 30 | FY20 Jun 30 |
|---|---|---|---|---|---|---|
| Revenue | $71.6M | $64.3M | $50.1M | $34.4M | $29.2M | $14.3M |
| Gross profit | $58.8M | $55.2M | $42.4M | $28.4M | $23.3M | $11.3M |
| Gross margin | 82.1% | 85.8% | 84.5% | 82.4% | 79.6% | 79.2% |
| Operating income | -$42.5M | -$56.6M | -$42.7M | -$27.5M | -$26.5M | -$42.7M |
| Net income | -$48.6M | -$61.8M | -$35.4M | -$26.7M | -$26.6M | -$42.0M |
| Net margin | −67.8% | −96.3% | −70.6% | −77.5% | −90.9% | −294.7% |
| Diluted EPS | $-1.74 | $-2.39 | $-1.40 | $-1.07 | $-1.17 | $-2.07 |
| EBITDA | -$40.2M | -$55.5M | -$41.7M | -$26.6M | -$25.7M | -$42.2M |
| Operating cash flow | -$31.2M | -$48.9M | -$38.0M | -$19.1M | -$25.9M | -$22.7M |
| Free cash flow | -$32.2M | -$58.1M | -$39.4M | -$19.5M | -$26.8M | -$23.3M |
| Diluted shares | 27.9M | 25.9M | 25.3M | 25.0M | 22.7M | 20.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.2M | $14.1M | $22.1M | $18.2M | $55.5M | $73.6M |
| Short-term investments | $7.9M | $21.8M | $66.9M | $61.2M | $29.6M | — |
| Total debt | $43.0M | $42.2M | $39.8M | $0.00 | $0.00 | $0.00 |
| Total assets | $56.4M | $79.7M | $111.6M | $98.3M | $116.0M | $82.5M |
| Total liabilities | $73.0M | $75.0M | $61.9M | $13.0M | $11.4M | $10.1M |
| Shareholders' equity | -$16.6M | $4.7M | $49.7M | $84.7M | $104.6M | $72.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology